SynthesisReviews in cardiovascular medicine2025
Diagnostic Performance of Positron Emission Tomography in the Assessment of Systemic Amyloidosis: A Systematic Review and Meta-Analysis.
Synthesis in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bioinformatic assessment of the potential amyloidogenicity of the human and evolutionarily more ancient proteomes.The Biochemical journal · 2026Article
- Diagnostic value of positron emission tomography using amyloid-binding radiotracers for cardiac amyloidosis: a systematic review and meta-analysis.European heart journal. Imaging methods and practice · 2026Article
- Imaging Advances in Light Chain Amyloidosis.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Positron emission tomography (PET) imaging with radiotracers can detect amyloid deposits in multiple organs. We conducted a systematic review and meta-analysis to evaluate the diagnostic performance of PET in patients with systemic amyloidosis. Methods: We searched PubMed, Cochrane, Embase, and Web of Science databases using the following keywords: "systemic amyloidosis" and "PET". Studies evaluating organ involvement in systemic amyloidosis using PET were included. The pooled relative risk (RR) values for each affected organ were calculated. Sensitivity, specificity, positive and negative likelihood ratios (LRs+ and LRs-), and diagnostic odds ratios (DORs) were individually calculated to assess cardiac involvement by PET, and a summary receiver operating characteristic (SROC) curve was generated. The diagnostic performance of PET was compared in separate subgroup analyses based on the type of radiotracer and amyloidosis subtype. Results: Among 10 studies, the pooled RR values for PET detecting organ involvement in the bone marrow, central nervous system (CNS), heart, lungs, muscles, pancreas, salivary glands, spleen, thyroid, and tongue were statistically significant. In the seven studies on cardiac involvement, the pooled sensitivity and specificity were 0.98 and 0.61, respectively, with an area under the curve (AUC) of 0.8954. Subgroup analysis showed Conclusion: PET imaging has significant clinical value in assessing organ involvement in systemic amyloidosis, particularly for the early detection of cardiac involvement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.